Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma
1. The median progression-free survival was 7.4 months in the rucaparib group and 5.7 months in the chemotherapy group for ...
